IsoRay, Inc. (NYSEAMERICAN: ISR) is having an incredibly strong start to the trading session this morning after announcing the release of a new product. Of course, the news led to excitement among investors, sending the stock screaming for the top. Today, we’ll talk about:
- The Build-Blu™ system;
- what we’re seeing from ISR as a result;
- and what we’ll be watching for ahead.
ISR Heads For The Top On Build-Blu™
As mentioned above, IsoRay is having an incredibly strong start to the trading session this morning after the company announced the release of a new product. In a press release issued early this moring, the company announced the upcoming release of its Build-Blu™ delivery system for real-time prostate brachytherapy.
In the release, ISR said the Build-Blu™ delivery system is a disposable, next generation, seed stranding device. The device allows prostate brachytherapists to affordably build custom-configured strands with Cesium-131 in the operating room. As a result, clinicians have the ability to individualize the procedure to the patients anatomy in real time. As a result of the new product, about 25% of treatment facilities for the prostate market that are using intra-operative techniques will have a new alternative solution. In a statement, William Cavanagh, Chief Science Officer and Chief Operating Officer at ISR, had the following to offer:
We are excited to respond to market needs with this innovative solution for intra-operative construction of brachytherapy strands… This is the first disposable device for building strands in the operating room and uses a proprietary design to efficiently construct the individualized treatment plan. Further, we believe this is the first new delivery system designed specifically for prostate brachytherapy in years.
The above statement was followed up by Thomas LaVoy, Chairman and CEO at ISR, here’s what he had to offer:
The Build-Blu delivery system will provide IsoRay with a differentiated solution, and position IsoRay to enter the intra-operative segment of the prostate brachytherapy market, estimated to account for approximately 25%, or $25 million of the $100 million prostate brachytherapy market… The development of this device is an important part of the focused strategy that we first implemented 18 months ago by increasing our investment in the development of new products. The disposable loader is the first of its kind that not only addresses a void in IsoRay’s product line, but also in the market, by offering an affordable solution to practitioners. The product launch scheduled for this summer expands our addressable market and should help us solidify our position as a leader in prostate brachytherapy.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dabble in the market is that the news causes moves. In this particular case, the news proved to be overwhelmingly positive. Not only did IsoRay announce the release of a new product, the product will go hand in hand with Cesium-131, potentially expanding the treatment’s reach. So, it’s no surprise that the stock is headed for the top this morning. At the moment (9:34), ISR is trading at $0.59 per share after a gain of $0.17 per share or 40.64% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on ISR. In particular, we’re interested in following the story surrounding the company’s Build-Blu™ system as well as the ongoing work surrounding Cesium-131. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!